D.E. Shaw & Co
PRDS

D.E. Shaw & Co’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

D.E. Shaw & Co’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,072
Closed -$175K – 5673
2022
Q2 		$175K Buy
57,072
+29,799
+109% +$182K ﹤0.01% 4593
2022
Q1 		$197K Sell
27,273
-10,766
-28% -$106K ﹤0.01% 4875
2021
Q4 		$623K Sell
38,039
-9,161
-19% -$107K ﹤0.01% 4277
2021
Q3 		$470K Hold
47,200
– – ﹤0.01% 4122
2021
Q2 		$472K Buy
+47,200
New +$474K ﹤0.01% 4065

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

D.E. Shaw & Co's PRDS Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 57,072 shares — an estimated $175K sold.

D.E. Shaw & Co first reported a position in PRDS in Q2 2021 and held it in 5 quarters. The position peaked at $623K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 57,072 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $175K.
  • D.E. Shaw & Co first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Pardes Biosciences, Inc. Common Stock position peaked at $623K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.